WA
HUMA icon

Waverly Advisors’s Humacyte HUMA Stock Holding History

Waverly Advisors’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.8K Buy
22,826
+3,775
+20% +$3.92K ﹤0.01% 1600
2025
Q4 		$18.3K Sell
19,051
-247,990
-93% -$351K ﹤0.01% 1462
2025
Q3 		$465K Sell
267,041
-3,813
-1% -$7.47K ﹤0.01% 871
2025
Q2 		$566K Sell
270,854
-7,337
-3% -$14.1K 0.01% 765
2025
Q1 		$474K Buy
278,191
+3,612
+1% +$13.6K 0.01% 793
2024
Q4 		$1.39M Buy
274,579
+211,009
+332% +$1.04M 0.02% 458
2024
Q3 		$346K Buy
63,570
+52,738
+487% +$348K 0.01% 652
2024
Q2 		$52K Buy
10,832
+82
+0.8% +$427 ﹤0.01% 794
2024
Q1 		$33.4K Buy
+10,750
New +$36.1K ﹤0.01% 685

Other funds holding HUMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AP
Antipodes Partners Royal Exchange, Australia $5.19B AUM 36.17% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Waverly Advisors's HUMA Position: Q1 2026 in Review

Waverly Advisors increased its Humacyte (HUMA) stake by 20% in Q1 2026, buying an estimated $3.92K and bringing the position to 22,826 shares worth $13.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1600.

Waverly Advisors first reported a position in HUMA in Q1 2024 and has held it in 9 quarters since. The position peaked at $1.39M in Q4 2024. 158 funds tracked by Wall St. Rank hold HUMA as of Q1 2026.

  • Waverly Advisors held 22,826 shares of Humacyte worth $13.8K as of Q1 2026.
  • Waverly Advisors bought 3,775 Humacyte shares in Q1 2026, an estimated $3.92K.
  • Humacyte made up ﹤0.01% of Waverly Advisors's portfolio in Q1 2026, its #1600 holding.
  • Waverly Advisors first reported a position in Humacyte in Q1 2024 and has held it in 9 quarters since.
  • Waverly Advisors's Humacyte position peaked at $1.39M in Q4 2024.
  • 158 funds tracked by Wall St. Rank held Humacyte as of Q1 2026.

Based on Waverly Advisors's 13F filing for Q1 2026, filed 15 May 2026.